@article{article_1618768, title={Bioavailability File: Bicalutamide}, journal={Fabad Eczacılık Bilimler Dergisi}, volume={50}, pages={429–446}, year={2025}, DOI={10.55262/fabadeczacilik.1618768}, author={Özaksun, Nihal Tuğçe and İnceçayır, Tuba}, keywords={Bicalutamide, bioavailability, pharmacokinetics, pharmacology, physicochemical properties}, abstract={The non-steroidal antiandrogen drug bicalutamide (BIC) is used in the treatment of prostate cancer. It blocks the stimulatory effects of androgens on the growth of prostate cancer cells by blocking binding to androgen receptors in the prostate gland. BIC is a racemic mixture, and the (R)-enantiomer exhibits the main effect. It has been reported that BIC provides the targeted antiandrogenic effect due to its high selectivity, but its adverse effects should be carefully monitored. (R)-BIC is slowly absorbed after oral administration, and its absorption is dose-dependent. The drug is extensively metabolized in the liver, while elimination is largely achieved by renal and hepatic pathways. BIC and its metabolites are found in almost equal amounts in urine and feces. This review comprehensively covers the physicochemical properties, analytical methods, pharmacokinetics, bioavailability, and pharmacology of BIC.}, number={2}, publisher={FABAD Ankara Eczacılık Bilimleri Derneği}